Tandem Therapeutics
Unlocking the matrix barrier to treat fibrotic diseases
Unlocking the matrix barrier to treat fibrotic diseases
Tandem Therapeutics is a Swiss biopharmaceutical company on a mission to Unlocking the matrix barrier to treat fibrotic diseases. Leveraging over 15 years of research and development at ETH Zürich and Paul Scherrer Institut, the company focuses on pioneering precision targeting approaches to fibrosis and fibrotic cancers. Tandem Therapeutics' therapeutic platform is centered around Matrix Targeting Peptides (MTP) designed to conditionally target disease-associated matrix alterations directly linked to various fibrotic diseases. The company secured its last Fr.150.00K grant investment from Venture Kick on 24 February 2023. Based in Switzerland and founded in 2023, Tandem Therapeutics is poised to make significant strides in the treatment of fibrotic diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
19 Apr 2024 |
| Grant | Fr.150.00K | 1 |
|
24 Feb 2023 |
No recent news or press coverage available for Tandem Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.